Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Semaglutide Wegovy / Ozempic Mechanism: GLP-1 receptor agonist (single target) Weight loss: ~15-17% body weight (STEP trials, 68 weeks) Dosing: Weekly injection, titrated from 0.25mg to 2.4mg Common side effects: Nausea, vomiting, diarrhea, constipation (typically transient) Availability: Longer track record, more widely available Cardiovascular data: SELECT trial demonstrated 20% reduction in major cardiovascular events Tirzepatide Zepbound / Mounjaro Mechanism: Dual GLP-1 + GIP receptor agonist (two targets) Weight loss: ~20-22% body weight (SURMOUNT trials, 72 weeks) Dosing: Weekly injection, titrated from 2.5mg to 15mg Common side effects: Similar GI profile to semaglutide
[DOI] [PubMed] [Google Scholar] 104.Abeyrathne E., Huang X., Ahn D.U
Crystallisation plates were set up using an SPT Labtech mosquito Xtal2 liquid handler
BPC-157 is a fascinating and potentially groundbreaking compound at the intersection of regenerative medicine and peptide science
US$ 25.88
US$ 26.83
US$ 24.98
US$ 20.35
US$ 24.91
US$ 23.68
US$ 23.10
US$ 28.89
